U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Media coverage

• Title	U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
  Media name/outlet	PipelineReview
  Country/Territory	Spain
  Date	26/10/22
  URL	https://pipelinereview.com/index.php/2022102681881/Antibodies/U.S.-FDA-Approves-TECVAYLI-teclistamab-cqyv-the-First-Bispecific-T-cell-Engager-Antibody-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html
  Persons	Ajai Chari